<DOC>
	<DOCNO>NCT00889460</DOCNO>
	<brief_summary>The purpose study determine safety tolerability several dos r Bet v1 administer sub-lingual tablet subject sensitise birch pollen .</brief_summary>
	<brief_title>Safety Tolerability Study rBet v1 SLIT Tablets</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>write consent Male female subject 18 60 year old general good health For woman child bear potential : Symptoms birch pollen induce allergic rhinitis least last 2 year . Sensitisation birch pollen demonstrate positive SPT birch pollen specific IgE level ( birch pollen r Bet v1 ) &gt; 0.70 kU/L screening . FEV1 least 80 % predict value screen . Subject accept comply fully protocol . Past current disease judge Investigator , may affect outcome study . History lifethreatening asthma , Asthma require daily treatment ( whatever pharmaceutical class ) . Pregnant lactate woman . Subject treat inhaled steroid within 4 week prior screen visit within 12 week prior screen visit . Subject previously receive desensitisation treatment birch pollen and/or betulaceae ( e.g. , hazel tree , alder ) plan start desensitisation treatment study . Symptoms treatment phase due sensitivity second allergen . Subjects treat ongoing immunotherapy another allergen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>rBet v 1</keyword>
	<keyword>Birch pollen allergy</keyword>
	<keyword>Sublingual Immunotherapy</keyword>
</DOC>